<DOC>
	<DOCNO>NCT01436929</DOCNO>
	<brief_summary>Tuberculosis worldwide common infectious disease effective first line anti-tuberculosis ( TB ) drug available isoniazid , rifampicin , ethambutol , pyrazinamide . However , anti-TB drug may induce hepatic injury result discontinuation anti-TB drug change anti-Tb drug regimen . Silymarin widely study effect hepatitis use hepatology . Therefore , investigator hypothesize prophylactic administration silymarin anti-TB drug may decrease incidence severity hepatotoxicity induce anti-TB drug .</brief_summary>
	<brief_title>Effect Prophylactic Use Silymarin Hepatotoxicity Induced Anti-tuberculosis Drugs</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Antitubercular Agents</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<criteria>subject diagnose tuberculosis base microbiological , biomolecular , pathological , radiographical finding expect administer antituberculosis drug include INH , RFP , PZA . adult &gt; =35 year old basal AST &gt; 40 IU/uL ALT &gt; 40 IU/uL pregnancy lactate woman case history adverse event silymarin</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>silymarin</keyword>
	<keyword>hepatotoxicity</keyword>
	<keyword>tuberculosis</keyword>
	<keyword>HREZ</keyword>
</DOC>